Literature DB >> 24577627

Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients.

Scott G Louis1, Misa Sato1, Travis Geraci1, Ross Anderson1, S David Cho1, Philbert Y Van1, Jeffrey S Barton1, Gordon M Riha1, Samantha Underwood1, Jerome Differding1, Jennifer M Watters1, Martin A Schreiber1.   

Abstract

IMPORTANCE: Enoxaparin sodium is widely used for deep vein thrombosis (DVT) prophylaxis, yet DVT rates remain high in the trauma and general surgery populations. Missed doses during hospitalization are common.
OBJECTIVE: To determine if missed doses of enoxaparin correlate with DVT formation. DESIGN, SETTING, AND PARTICIPANTS: Data were prospectively collected among 202 trauma and general surgery patients admitted to a level I trauma center. MAIN OUTCOMES AND MEASURES: Deep vein thrombosis screening was performed using a rigorous standardized protocol.
RESULTS: The overall incidence of DVT was 15.8%. In total, 58.9% of patients missed at least 1 dose of enoxaparin. The DVTs occurred in 23.5% of patients who missed at least 1 dose and in 4.8% of patients who did not (P < .01). On univariate analysis, the need for mechanical ventilation (71.8% vs 44.1%), the performance of more than 1 operation (59.3% vs 40.0%), and male sex (75% vs 56%) were associated with DVT formation (P < .05 for all). A bivariate logistic regression was then performed, which revealed age 50 years or older and interrupted enoxaparin therapy as the only independent risk factors for DVT formation. The DVT rate did not differ between trauma and general surgery populations or in patients receiving once-daily vs twice-daily dosing regimens. CONCLUSIONS AND RELEVANCE: Interrupted enoxaparin therapy and age 50 years or older are associated with DVT formation among trauma and general surgery patients. Missed doses occur commonly and are the only identified risk factor for DVT that can be ameliorated by physicians. Efforts to minimize interrupted enoxaparin prophylaxis in patients at risk for DVT should be optimized.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24577627     DOI: 10.1001/jamasurg.2013.3963

Source DB:  PubMed          Journal:  JAMA Surg        ISSN: 2168-6254            Impact factor:   14.766


  37 in total

1.  What the 2018 ASH venous thromboembolism guidelines omitted: nonadministration of pharmacologic prophylaxis in hospitalized patients.

Authors:  Oluwafemi P Owodunni; Brandyn D Lau; Michael B Streiff; Peggy S Kraus; Deborah B Hobson; Dauryne L Shaffer; Kristen L W Webster; Mujan Varasteh Kia; Christine G Holzmueller; Elliott R Haut
Journal:  Blood Adv       Date:  2019-02-26

2.  Role network measures to assess healthcare team adaptation to complex situations: the case of venous thromboembolism prophylaxis.

Authors:  Megan E Salwei; Pascale Carayon; Ann S Hundt; Peter Hoonakker; Vaibhav Agrawal; Peter Kleinschmidt; Jason Stamm; Douglas Wiegmann; Brian W Patterson
Journal:  Ergonomics       Date:  2019-04-30       Impact factor: 2.778

3.  Utilization rates of enoxaparin and heparin in deep venous thrombosis prophylaxis after education and electronic order change at a single institution: a quality improvement study.

Authors:  Linda Hoang; Shahidul Islam; Alexander Hindenburg
Journal:  J Thromb Thrombolysis       Date:  2018-11       Impact factor: 2.300

4.  Venous thromboembolism in emergency general surgery patients: a single-centre retrospective cohort study

Authors:  Mei Yang; Patrick B. Murphy; Laura Allen; Nathalie Sela; Shaylan Govind; Ken Leslie; Kelly Vogt
Journal:  Can J Surg       Date:  2020-02-26       Impact factor: 2.089

5.  Comparative Effectiveness of Enoxaparin vs Dalteparin for Thromboprophylaxis After Traumatic Injury.

Authors:  Todd A Miano; Adam Cuker; Jason D Christie; Niels Martin; Brian Smith; Amy T Makley; Wensheng Guo; Sean Hennessy
Journal:  Chest       Date:  2017-08-18       Impact factor: 9.410

6.  Association of the Risk of a Venous Thromboembolic Event in Emergency vs Elective General Surgery.

Authors:  Samuel W Ross; Kali M Kuhlenschmidt; John C Kubasiak; Lindsey E Mossler; Luis R Taveras; Thomas H Shoultz; Herbert A Phelan; Caroline E Reinke; Michael W Cripps
Journal:  JAMA Surg       Date:  2020-06-01       Impact factor: 14.766

7.  Preoperative Chemoprophylaxis is Safe in Major Oncology Operations and Effective at Preventing Venous Thromboembolism.

Authors:  Luke V Selby; Mindy Sovel; Daniel D Sjoberg; Margaret McSweeney; Damon Douglas; David R Jones; Peter T Scardino; Gerald A Soff; Nicola Fabbri; Kent Sepkowitz; Vivian E Strong; Inderpal S Sarkaria
Journal:  J Am Coll Surg       Date:  2015-12-15       Impact factor: 6.113

8.  Dynamic coagulability after injury: Is delaying venous thromboembolism chemoprophylaxis worth the wait?

Authors:  Joshua J Sumislawski; Lucy Z Kornblith; Amanda S Conroy; Rachael A Callcut; Mitchell Jay Cohen
Journal:  J Trauma Acute Care Surg       Date:  2018-11       Impact factor: 3.313

9.  Prescriber knowledge and attitudes regarding non-administration of prescribed pharmacologic venous thromboembolism prophylaxis.

Authors:  Kara L Piechowski; Stacy Elder; Leigh E Efird; Elliott R Haut; Michael B Streiff; Brandyn D Lau; Peggy S Kraus; Cynthia S Rand; Victor O Popoola; Deborah B Hobson; Norma E Farrow; Dauryne Shaffer; Kenneth M Shermock
Journal:  J Thromb Thrombolysis       Date:  2016-11       Impact factor: 2.300

10.  Factors associated with women's adherence to postpartum thromboprophylaxis.

Authors:  Amihai Rottenstreich; Adi Karlin; Yosef Kalish; Gabriel Levin; Misgav Rottenstreich
Journal:  J Thromb Thrombolysis       Date:  2020-02       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.